15.232 Business Model Innovation for Global Health A Preliminary Assessment of ColaLife

October 2013

1



Executive Summary:

How can ColaLife scale the distribution of diarrhea treatment kits?

ColaLife is a **nonprofit** that aims to leverage private sector **distribution networks** to deliver diarrhea treatment kits to remote areas in Africa

- <u>Situation</u>: Diarrhea accounts for 11% of deaths in children under five but only 39% of affected children have access to life-saving ORS treatment
- <u>Complication</u>: Infrastructure and health systems constraints make it challenging to reach the end-user
- Question: How can ColaLife scale its distribution?
- Analysis: Interview with Simon Berry, Founder and CEO; secondary research
- <u>Recommendations:</u> To increase utilization rates, ColaLife should a) *build consumer awareness*, and b) *increase incentives for retailers* in the short term; in the long term, ColaLife should c) *grow the number of distribution channels*, and d) *explore direct-sales models* to increase penetration rates in hard to reach areas

Context: Gaps in Diarrhea Treatment Delivery

Drug Manufacturer

- 75% of diarrhea deaths can be prevented by ORS and zinc supplements
- Manufacturers cannot deliver
 ORS to remote areas, or assure
 safety due to counterfeit and altered medications

Distribution Gap

- Public and private health care facilities in severely-affected countries are often not able to provide consistent and affordable supply of ORS and zinc supplements
- Existing distribution is inadequate
 - Distance remote areas lack access to medicines, especially during rainy season when treatment is most needed
 - High Cost Transportation accounts for ~40% of treatment costs
 - **Stock-Outs** Medicine availability is 38% at public facilities and 60% at private facilities.

End User (mothers)

- Mothers lack affordable and reliable access to ORS, and often do not know how to mix ORS for proper dose
- Children risk increased mortality from preventable diarrhea

Sources: WHO, "Children: Reducing Mortality" Factsheet. September 2012. http://www.who.int/mediacentre/factsheets/fs178/en/; UNICEF, "Pneumonia and Diarrhea" report. June 2012. http://www.unicef.org/media/files/UNICEF_P_D_complete_0604.pdf; ColaLife website. Accessed September 19, 2013. http://www.colalife.org

Goal: Reduce child mortality through alliances

Mission

Build **novel partnerships** to alleviate poverty and **improve health** in the developing world through **innovation**

Goals & Activities

- Reduce child mortality from simple causes, such as dehydration from diarrhea
- Promote "unlikely alliances" to provide access to affordable, essential drugs
 - By opening up private sector supply chains for 'social products' such as oral rehydration salts and zinc supplements
 - Currently conducting pilot in Zambia, copying Coca-Cola's business model
 ***"DESIGN a desirable product"**: easy to use Anti-Diarrhea Kits (Kit Yamoyo)
 ***"MARKET like mad"**: facilitate demand/use of kits through social marketing
 ***"DISTRIBUTE profitably"**: same distribution channel as a bottle of Coke

Target consumers

- Mothers/care-givers of children with diarrhea in two remote districts in Zambia
 - Sold 24,565 kits during 12-month trial (90% of the kits have been purchased with vouchers and 10% with cash)

Sources: ColaLife website. Accessed September 28, 2013 http://www.colalife.org/aims/, http://www.colalife.org/impact/.


Images and components of The ColaLife Anti-Diarrhoea Kit removed due to copyright restrictions. See the ColaLife website for information.

Strategy: A New Distribution Channel

ColaLife leverages Coca-Cola's network to distribute ORS Kits to Remote Areas

	_				
	Drug Manufacturer	Wholesaler Distributor Retailer	End User (mothers)		
Unmet Need	 Inability to distribute ORS and zinc to rural areas 	 Lack of incentives to participate in ORS and zinc distribution 	 Lack of access and willingness to pay for life-saving ORS and zinc treatment 		
Value Proposition	 Third distribution channel (not via public or private clinics) improves access to ORS and zinc 	 New distribution approach leverages existing infrastructure to generate additional revenue for wholesalers, distributors, and retailers Turn end user "need" into "demand" and cultivate willingness to pay through aggressive social marketing and initial subsidized biz model 	 Reliable, convenient (with clear dosage instructions), and affordable ORS sold by local retailers Mobile verification assures safety 		
Value Measures*	 Number of diarrhea kits distributed in rural areas 	 Revenue generated Profit margins 	 Affordability Ease of access Ease of use Utilization Adherence Reduced diarrhea mortality 		


Operations: Lean non-profit managing partners



Team of 3 and volunteers at ColaLife manage entire process

Sources: ColaLife website. Accessed September 28, 2013. http://www.colalife.org; ColaLife Trial Plan.

History: Idea conception to pilot



Sources: ColaLife website. Accessed September 28, 2013. http://www.colalife.org; ColaLife Trial Plan.

Value Measures

Key Outputs and Outcomes	Associated Metric	Current ColaLife Measure?
Coverage	Number of anti-diarrhea kits delivered	
Utilization level	Proportion of children with diarrhea who used ORS and zinc	
Adherence	Proportion of children receiving the kit who have completed the 10 day course of drugs	
Child Mortality	In the areas where ColaLife operates, diarrhea-related deaths, per 100,000 children under 5 years of age	

- Currently, ColaLife is conducting an evaluation in 4 districts (2 target and 2 control), covering 625 households and 45 retailers in each district
- While the trial includes a baseline, midline (at 6 months), and final (at 12 months) survey, it is limited to tracking **outputs** and **intermediate outcomes**
- To measure its real impact, ColaLife would need to track its progress on additional outcomes (in particular, child mortality rates attributable to diarrhea)

Source: ColaLife blog. Accessed September 19, 2013. http://www.colalife.org/2013/08/22/final-survey-kicks-off-feelings-of-slight-relief/

Core Strengths and Capabilities

Unique role in global health

- Ability to fill a strategic gap in the global public health arena, by bringing together multiple key stakeholders to tackle diarrhea-related child mortality
- Innovative approach to leverage market forces

Replicable, low-cost solution¹

- Lean organization, low overhead
- Leveraging existing infrastructure for distribution

Local ownership


- Local determination of what is needed and how it should be distributed (e.g., retailers decide whether to distribute free, at cost, or with positive profit margins)
- Grassroots empowerment

¹ We discuss issues of long-term sustainability further in this deck

Key Challenges and Implications for Success

Focus of our recommendations (next page)*

reduce dosage to save money)



* We chose these three areas for recommendation focus because we felt that these are the areas where ColaLife can most realistically achieve results 11

Recommendations and Expected Impact

Recommendations

- 1. Increase revenues to improve ColaLife's profitability
 - Explore opportunities for **revenue-generation via** advertising
 - Analyze impact of vouchers on end-user willingness to pay to identify optimal pricing

- Identify new potential distribution partners

cost ways of leveraging their distribution

(beyond Coca-Cola) and consider no-cost/low-

networks directly (e.g., similar to using space in

2. Expand distribution and reduce costs to drive

profitability

Coke boxes)

Potential Next Steps

- Contact telecommunications, consumer product, & fin. services companies to explore marketing opportunities to subsidize kit costs
- Engage consumer insights firm to assess optimal price level to maximize demand & profits for retailers
- Research additional distribution channels to augment product delivery (e.g., telecom booths, banks, schools)
- Recruit volunteers to evaluate successful direct sales models (e.g., Avon, L'Oreal Matrix, Natura) to identify lessons and distribution strategies
- Convene roundtable for Zambian
 MoH, NGOs, and media to develop
 strategies to build product awareness

3

3. Improve consumer awareness of ColaLife's products

- Engage end-users in sales process in 1 of 2 ways:
 - Direct sale (e.g., Avon model)
 - Info distribution (e.g., leaflets)
- Engage healthcare workers in awareness-building

Vision for the Future

Maintain

easy-to-use packaging and MNC distribution partnerships



Expand

demand through education and supply through micro-distribution



Achieve scale to reduce child mortality from diarrhea



Images courtesy Simon Berry on Flickr. License: CC:BY-SA. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

Vision for the Future

Maintain

easy-to-use packaging and MNC distribution partnerships



Expand

demand through education and supply through micro-distribution



Achieve

scale to reduce child mortality from diarrhea



Images courtesy Simon Berry on Flickr. License: CC:BY-SA. This content is excluded from our Creative Commons license. For more information, see http://ocw.mit.edu/help/faq-fair-use/.

- Maintain easy-to-use packaging that provides proper dose for one child and a container for mixing the ORS solution
- Maintain and expand distribution partnerships with MNCs, including SABMiller, Coca-Cola, and others
- Increase consumer awareness by partnering with media and mobile carriers
- Increase incentives for retailers by generating additional revenue from advertising in Yamoyo kits
- ✓ Expand number of distribution channels (e.g., retailers, clinics, telecommunications) to increase access to Kits Yamoyo
- ✓ Explore direct-sales models (e.g., Avon, Natura, L'Oreal Matrix), where possible, to increase penetration in hard-to-reach areas

- Increase utilization rate in covered areas
 - Endline survey shows current utilization is 48%
- Contribute to reducing U5MR from diarrhea in covered areas
 - Diarrhoea accounts for 11% of global deaths among children under 5 years old (2010)¹
 - In Zambia, under five mortality rate is 83/1,000 (2011). MDG target is 64/1,000 by 2015 ²

Image sources: ColaLife website. Accessed September 28, 2013 http://www.colalife.org/aims/. ¹ UNICEF, "Pneumonia and Diarrhea" report. June 2012. http://www.unicef.org/media/files/UNICEF_P_D_complete_0604.pdf; ² UNICEF. *Levels and Trends in Child Mortality: Report 2012*. UNICEF. New York: 2012. http://www.unicef.org.uk/Documents/UNICEF%20Child%20mortality%20report%202012.pdf. Accessed September 27, 2013.

Appendix: Sources

ColaLife blog. Last accessed September 28, 2013. http://www.colalife.org/2013/08/22/final-survey-kicks-off-feelings-of-slight-relief/.

ColaLife Trial Plan. Executive Summary and Main sections, July 2011 version. Shared by Simon over email on September 17, 2013.

ColaLife website. Last accessed September 28, 2013. http://www.colalife.org, http://www.colalife.org/aims/, http://www.colalife.org/impact/.

Day, Peter. "ColaLife: Turning profits into healthy babies." July 2013. http://www.bbc.co.uk/news/magazine-23348408.

Kayte, Leon. "ColaLife Uses Crates of Coke to Save Lives in Africa." October 2012. http://www.triplepundit.com/2012/10/colalife-crates-coke-africa-save-lives/.

Maly,Tim. "ColaLife rides Coke's distribution to deliver essential medicine to remote villages." March 2013. http://www.wired.co.uk/news/archive/2013-03/28/colalife.

Berry, Simon. Interview by Kate Fedosova, Yuko Hirose, Darya Nachinkina, Sharon Lee-Quick, and Leeann To. Interview via Skype. October 7, 2013.

UNICEF. Levels and Trends in Child Mortality: Report 2012. New York: 2012. http://www.unicef.org.uk/Documents/UNICEF%20Child%20mortality%20report%202012.pdf.

UNICEF. "Pneumonia and Diarrhea" report. June 2012. http://www.unicef.org/media/files/UNICEF_P_D_complete_0604.pdf.

Viney, Mark. "Making Medicine as Ubiquitous as Coca-Cola in Rural Africa." August 2013. http://www.slate.com/articles/health_and_science/new_scientist/2013/08/colalife_simon_berry_is_trying_to_make_me dicine_as_ubiquitous_as_coca_cola.html.

WHO, "Children: Reducing Mortality" Factsheet. September 2012. http://www.who.int/mediacentre/factsheets/fs178/en/.

Appendix: ColaLife Business Model


Visual diagram of ColaLife business model removed due to copyright restrictions. See the ColaLife website for information.

Sources: ColaLife website. Accessed September 28, 2013 http://www.colalife.org/aims/.

Appendix: Diarrhea Care Delivery Value Chain

ColaLife focuses on the Initiating Therapy vertical of health care delivery chain, by:

- 1) Engaging and informing its supply chain partners and end users
- 2) Providing an end-to-end distribution solution for life-saving diarrhea drugs



Verticals of health care chain engagement

17

Appendix: Under Five Mortality Rate

Under five mortality rate in Zambia is 83 deaths per 1,000 live births; this rate is 19 deaths higher than MDG target for 2015

	Under-five mortality rate (USMR) (deaths per 1,000 live births)												
	1990			2000			2011			Millennium Development	Annual rate of reduction (ARR) (percent) 1990–2011		
Country or territory	USMR	Lower	Upper	USMR	Lower	Upper bound	USMR	Lower	Upper	Goal target for 2015	ARR	Lower	Upper bound
Thailand	35	32	39	19	17	22	12	8	17	12	5.0	3.3	7.0
The former Yugoslav Republic of Macedonia	38	34	40	16	16	18	10	8	12	13	6.5	5.4	7.1
Timor-Leste	180	164	199	109	100	121	54	46	72	60	5.7	4.2	6.7
Togo	147	138	161	128	116	147	110	92	139	49	1.4	0.4	2.1
Tonga	25	22	29	20	16	25	15	11	22	8	2.2	1.1	3.8
Trinidad and Tobago	37	33	44	32	27	41	28	21	39	12	1.4	0.4	2.3
Tunisia	51	42	57	30	25	34	16	13	20	17	5.5	4.5	6.4
Turkey ⁴	72	66	76	35	31	39	15	12	20	24	7.4	5.9	8.6
Turkmenistan	94	86	103	71	62	86	53	41	74	31	2.8	1.3	3.8
Tuvalu	58	51	64	43	38	48	30	24	40	19	3.1	1.4	4.4
Uganda	178	168	188	141	129	146	90	84	105	59	3.3	2.4	3.6
Ukraine	19	18	22	19	17	20	10	9	12	7	3.1	2.2	4.2
United Arab Emirates	22	21	25	12	12	13	7	6	7	7	5.8	5.5	6.8
United Kingdom	9	9	10	7	6	7	5	5	6	3	2.8	2.3	3.1
United Republic of Tanzania	158	148	164	126	115	129	68	62	81	53	4.0	3.1	4.4
United States	11	11	12	9	8	9	8	7	8	4	2.0	1.6	2.3
Uruguay	23	22	25	17	16	18	10	9	12	8	3.8	3.3	4.4
Uzbekistan	75	70	85	61	54	73	49	38	66	25	2.1	0.7	3.5
Vanuatu	39	34	45	23	20	29	13	10	18	13	5.1	3.9	6.0
Venezuela (Bolivarian Republic of)	31	29	34	22	21	24	15	14	16	10	3.4	2.9	4.0
Viet Nam	50	44	55	34	31	37	22	20	24	17	4.0	3.2	4.7
Yemen	126	116	136	99	85	110	77	58	92	42	2.4	1.5	3.6
Zambia	193	175	195	154	142	167	83	76	110	64	4.0	2.4	4.3
Zimbabwe	79	75	86	106	97	115	67	53	74	26	0.8	0.3	2.1

Source: UNICEF. Levels and Trends in Child Mortality: Report 2012. UNICEF. New York: 2012. http://www.unicef.org.uk/Do cuments/UNICEF%20Child %20mortality%20report%20 2012.pdf. Accessed September 27, 2013.

Appendix: Questions for Further Exploration

Partners	 What role is Coca-Cola playing now, since Kit Yamoyos* are no longer bundled with bottles? To what extent does ColaLife leverage Coca-Cola's distribution network (vs. just the local relationships)? 								
	Is there room to expand other corporate or public partnerships?								
Pricing and	Pricing and Demand (with implications for sustainability):								
demand	 Right now, the price of Kit Yamoyos (\$1) is fully subsidized by vouchers provided to the end user (despite ColaLife's end-user marketing efforts, it still appears to be a push model – not a pull model). 								
	 Without these vouchers, does the price of the Kit Yamoyo align with the customer's willingness/ability to pay? 								
	 What level of education/marketing (of the end-user) is required to shift this into a pull model for the end-user? 								
	 Also, if prices have to be lowered, will ColaLife be able to provide profit for distributors at every level of the supply chain? 								
Sustainability	 Financial sustainability: How can ColaLife achieve financial sustainability with regard to its central operations (assuming prices cannot cover indirect operating costs)? 								
Product use	 Product Use – End-user compliance/adherence appears to be an issue (in order to be effective, drugs need to be taken daily for 10 days), how can ColaLife improve compliance? 								

* Kit Yamoyos are sachets with ORS and other materials. They used to be distributed via wedge-shaped AidPods that were put into Coke boxes 19

The Cola Road Trailer http://vimeo.com/61315023

15.232 Business Model Innovation: Global Health in Frontier Markets Fall 2013

For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.